FDA warning letter
US$ 28.94
foxo4 dri senolytic peptide human trial Development of a novel by precise disruption of FOXO4-p53 complex foxo4-dri peptide senolytic human trial
Description
We have demonstrated that the organoids are able to produce AT, A1AT, and high levels of FVII and other vitamin K-specific factors, including FII and FX
Click any document to view in detail
The results are graphically presented as the meanS.E.M
It corresponds to a partial sequence of a protein originally discovered during research on human gastric juice
